Doxorubicin changes Bax /Bcl-xL ratio, caspase-8 and 9 in breast cancer cells

Advanced Pharmaceutical Bulletin

Volumn 5, Issue 3, 2015, Pages 351-359

  Sharifi, Simin ^a   Barar, Jaleh ^a,b   Hejazi, Mohammad Saeid ^a   Samadi, Nasser ^a,b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Bax Bcl xL; Breast cancer; Caspase 9; Doxorubicin; MCF 7

Indexed keywords

CASPASE 8; CASPASE 9; DOXORUBICIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL XL;

ARTICLE; BAX GENE; BCL XL GENE; BREAST CANCER CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; INCUBATION TIME; UPREGULATION;

EID: 84983573942     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.15171/apb.2015.049     Document Type: Article

References (62)

1. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997;88(3):347-54. doi: 10.1016/s0092-8674(00)81873-5.
2. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011;30(1):87. doi: 10.1186/1756-9966-30-87.
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108(2):153-64. doi: 10.1016/s0092-8674(02)00625-6.
4. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281(5381):1305-8. doi: 10.1126/science.281.5381.1305.
5. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000;7(12):1182-91. doi: 10.1038/sj.cdd.4400781.
6. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25(34):4798-811. doi: 10.1038/sj.onc.1209608.
7. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22(53):8543-67. doi: 10.1038/sj.onc.1207107.
8. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998;12(11):1551-70. doi: 10.1101/gad.12.11.1551.
9. Olsson M, Zhivotovsky B. Caspases and cancer. Cell Death Differ 2011;18(9):1441-9. doi: 10.1038/cdd.2011.30.
10. Fulda S, Debatin KM. Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 2004;4(7):569-76. doi: 10.2174/1568009043332763.
11. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010;37(3):299-310. doi: 10.1016/j.molcel.2010.01.025.
12. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993;53(19):4701-14.
13. Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 2011;351(1-2):41-58. doi: 10.1007/s11010-010-0709-x.
14. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74(4):609-19. doi: 10.1016/0092-8674(93)90509-o.
15. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011;18(9):1414-24. doi: 10.1038/cdd.2011.17.
16. Reed JC. Bcl-2 family proteins. Oncogene 1998;17(25):3225-36. doi: 10.1038/sj.onc.1202591.
17. Zhang H, Heim J, Meyhack B. Redistribution of Bax from cytosol to membranes is induced by apoptotic stimuli and is an early step in the apoptotic pathway. Biochem Biophys Res Commun 1998;251(2):454-9. doi: 10.1006/bbrc.1998.9485.
18. Lindsay J, Esposti MD, Gilmore AP. Bcl-2 proteins and mitochondria--specificity in membrane targeting for death. Biochim Biophys Acta 2011;1813(4):532-9. doi: 10.1016/j.bbamcr.2010.10.017.
19. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, et al. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 1996;97(11):2651-9. doi: 10.1172/jci118715.
20. Simonian PL, Grillot DaM, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997;90(3):1208-16.
21. Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG, et al. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 1998;47(2):129-40. doi: 10.1023/a:1005940832123.
22. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997;3(4):230-7.
23. Kojima H, Endo K, Moriyama H, Tanaka Y, Alnemri ES, Slapak CA, et al. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem 1998;273(27):16647-50. doi: 10.1074/jbc.273.27.16647.
24. Rodriguez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006;12(34):4411-25. doi: 10.2174/138161206779010495.
25. Adjei AA, Rowinsky EK. Novel anticancer agents in clinical development. Cancer Biol Ther 2003;2(4 Suppl 1):S5-15. doi: 10.4161/cbt.218.
26. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54 Suppl 4:1-7.
27. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57(7):727-41. doi: 10.1016/s0006-2952(98)00307-4.
28. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther 2008;83(1):26-36. doi: 10.1038/sj.clpt.6100449.
29. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001;11(11):S22-6. doi: 10.1016/S0962-8924(01)02124-9.
30. Ghanbari P, Mohseni M, Tabasinezhad M, Yousefi B, Saei AA, Sharifi S, et al. Inhibition of survivin. restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol 2014;174(2):667-81. doi: 10.1007/s12010-014-1125-6.
31. Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M, et al. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev 2014;15(13):5311-6. doi: 10.7314/apjcp.2014.15.13.5311.
32. Samadi N, Ghanbari P, Mohseni M, Tabasinezhad M, Sharifi S, Nazemieh H, et al. Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells. J Cancer Res Ther 2014;10(3):715-21. doi: 10.4103/0973-1482.139152.
33. Sharifi S, Barar J, Hejazi MS, Samadi N. Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel. Asian Pac J Cancer Prev 2014;15(20):8617-22. doi: 10.7314/apjcp.2014.15.20.8617.
34. Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997;57(15):3071-8.
35. Hamedeyazdan S, Fathiazad F, Sharifi S, Nazemiyeh H. Antiproliferative activity of Marrubium persicum extract in the MCF-7 human breast cancer cell line. Asian Pac J Cancer Prev 2012;13(11):5843-8. doi: 10.7314/apjcp.2012.13.11.5843.
36. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 2003;228(9):995-1003.
37. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78(4):539-42. doi: 10.1016/0092-8674(94)90518-5.
38. Debatin KM. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Inst 1997;89(11):750-1. doi: 10.1093/jnci/89.11.750.
39. Lukyanova NY, Rusetskya NV, Tregubova NA, Chekhun VF. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 2009;31(2):87-91.
40. Taherian A, Mazoochi T. Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. Iran J Basic Med Sci 2012;15(1):669-77.
41. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994;45(4):649-56.
42. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281(5381):1309-12. doi: 10.1126/science.281.5381.1309.
43. Rao L, White E. Bcl-2 and the ICE family of apoptotic regulators: making a connection. Curr Opin Genet Dev 1997;7(1):52-8. doi: 10.1016/s0959-437x(97)80109-8.
44. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002;62(16):4592-8.
45. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81(11):3091-6.
46. Leung LK, Wang TT. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat 1999;55(1):73-83. doi: 10.1023/a:1006190802590.
47. Tudor G, Aguilera A, Halverson DO, Laing ND, Sausville EA. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 2000;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
48. Gross A. BCL-2 proteins: regulators of the mitochondrial apoptotic program. IUBMB life 2001;52(3-5):231-6. doi: 10.1080/15216540152846046.
49. Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 2002;20(6):1297-303. doi: 10.3892/ijo.20.6.1297.
50. Gonzalez MS, De Brasi CD, Bianchini M, Gargallo P, Moiraghi B, Bengio R, et al. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia. Blood Cells Mol Dis 2010;45(3):192-6. doi: 10.1016/j.bcmd.2010.07.011.
51. Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998;391(6666):496-9. doi: 10.1038/35160.
52. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998;95(9):4997-5002. doi: 10.1073/pnas.95.9.4997.
53. Kagawa S, Pearson SA, Ji L, Xu K, Mcdonnell TJ, Swisher SG, et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther 2000;7(1):75-9. doi: 10.1038/sj.gt.3301048.
54. Kumar S. Regulation of caspase activation in apoptosis: implications in pathogenesis and treatment of disease. Clin Exp Pharmacol Physiol 1999;26(4):295-303. doi: 10.1046/j.1440-1681.1999.03031.x.
55. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a reiew of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012;45(6):487-98. doi: 10.1111/j.1365-2184.2012.00845.x.
56. Liang Y, Yan C, Schor NF. Apoptosis in the absence of caspase 3. Oncogene 2001;20(45):6570-8. doi: 10.1038/sj.onc.1204815.
57. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A 1998;95(8):4386-91. doi: 10.1073/pnas.95.8.4386.
58. Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T, Saijo N. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 1999;6(1):33-7. doi: 10.3892/or.6.1.33.
59. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273(16):9357-60. doi: 10.1074/jbc.273.16.9357.
60. Ferreira KS, Kreutz C, Macnelly S, Neubert K, Haber A, Bogyo M, et al. Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis 2012;17(5):503-15. doi: 10.1007/s10495-011-0691-0.
61. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17(6):1675-87. doi: 10.1093/emboj/17.6.1675.
62. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001;61(1):348-54.